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Abstract
Purpose: Current literature shows different findings on the contemporary trends of distant-stage 
prostate cancer incidence, in part, due to low study population coverage and wide age groupings. 
This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age 
(5-year grouping), race, and ethnicity using nationwide cancer registry data.
Methods: Data on prostate cancer cases came from the 2004—2014 United States Cancer 
Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-
year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated 
annual percentage change (APC).
Results: We identified 2,137,054 incident prostate cancers diagnosed during 2004—2014, with 
an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence 
significantly decreased during 2004—2010 (APC = −1.2) and increased during 2010—2014 (APC 
= 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older 
than or equal to 50 years except men aged 65—74 and older than or equal to 85 years, in men with 
white race (APC = 3.9), and non-Hispanic ethnicity (APC = 3.5).
Conclusions: Using data representing over 99% of U.S. population, we found that incidence 
rates of distant-stage prostate cancer significantly increased during 2010—2014 among men in 
certain ages, in white, and with non-Hispanic ethnicity.
Keywords
Prostate cancer; Cancer incidence; Cancer stage
*
 Corresponding author. Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers for Disease 
Control and Prevention, 4770 Buford Hwy, Mail Stop F-76, Atlanta, GA 30341. Tel.: 770-488-3030; fax: 770-488-4639, 
ffa2@cdc.gov (J. Li). 
Disclosure: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention.
No financial conflict of interest for all authors and no funding sources claimed.
HHS Public Access
Author manuscript
Ann Epidemiol. Author manuscript; available in PMC 2018 August 07.
Published in final edited form as:
Ann Epidemiol. 2018 May ; 28(5): 328–330. doi:10.1016/j.annepidem.2018.03.001.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Background
With the introduction of prostate-specific antigen (PSA) testing in the mid-1980s, the 
incidence rate of distant-stage prostate cancer has decreased more than 60% during the last 
two decades [1]. Concluding that harms from PSA-based screening outweighed benefits, the 
United States Preventive Services Task Force recommended against routine PSA-based 
screening for men older than or equal to 75 years of age in 2008 and all ages in 2012 [2]. 
Studies have consistently shown that PSA testing prevalence and localized/regional prostate 
cancer incidence rates declined following these recommendations [3—6]. However, current 
literature shows different findings on the contemporary trends of distant-stage prostate 
cancer incidence. These differences might be because of low population coverage (≤28%) 
and wide age groupings [3,7,8].
Objective
To examine the stage-specific incidence rates and trends of prostate cancer by age (5-year 
grouping), race, and ethnicity using nationwide cancer registry data.
Methods and findings
Data on prostate cancer cases came from the United States Cancer Statistics (USCS) data 
set, which includes the National Program of Cancer Registries and Surveillance, 
Epidemiology, and End Results (SEER) programs. Incidence data for all registries except 
Nevada met USCS publication criteria (http://www.cdc.gov/cancer/npcr/standards.htm) 
during 2004—2014, and represented 99.1% of the U.S. population. We identified prostate 
cancer cases using the International Classification of Diseases for Oncology, Third Edition 
site code C619 and behavior code 3. We excluded 1160 autopsy or death certificate-only 
cases (0.05%) and 72,232 nonmicroscopically confirmed cases (3.27%). We calculated 
stage-specific (localized, regional, distant, and unstaged) incidence and 95% confidence 
intervals by age (5-year age grouping), race (white, black, Asian/Pacific Islander, and 
American Indian/Alaska Native), and ethnicity (Hispanic and non-Hispanic) using 
SEER*Stat. Rates for all variables except age were age standardized to the 2000 U.S. 
standard population. To measure the changes in rates over time, we calculated annual 
percentage change (APC) using Joinpoint regression software. A maximum of two join 
points were used to determine a change of direction in trends during our study period. APCs 
were considered to be statistically significant if P <.05.
We identified 2,137,054 incident prostate cancers diagnosed during 2004—2014. The age-
adjusted incidence rate was 453.8 per 100,000. Of these cases, 80% were localized, 10% 
were regional, 4% were distant, and 5% were unstaged (data not shown). Table 1 shows 
cancer stage-specific incidence rates and trends by age, race, and ethnicity. For localized- 
and regional-stage prostate cancers, incidence rates were stable during 2004—2007 and 
significantly declined during 2007—2014. In contrast, distant-stage prostate cancer 
incidence significantly decreased during 2004—2010 (APC = −1.2) and increased during 
2010—2014 (APC = 3.3). Significant increases in distant prostate cancer incidence also 
occurred in men aged older than or equal to 50 years except men aged 65—74 and older 
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than or equal to 85 years, and in men with white race (APC = 3.9), or non-Hispanic ethnicity 
(APC = 3.5).
Discussion
Using data representing over 99% of U.S. population, we found that incidence rates of 
distant-stage prostate cancer significantly increased during 2010—2014 among men aged 
older than or equal to 50 years. Stratified analyses by age, race, and ethnicity suggest that 
this increase occurred among men of white race, non-Hispanic ethnicity, and men aged 50—
64 and 75—84 years.
Two previously published SEER studies showed stable trends of distant-stage prostate 
cancer among men aged less than 75 years [3,5]. However, three other SEER studies 
reported increasing trends among men aged 45—64, 50—69, and 45—69 years, respectively 
[7,9,10]. Past studies reported either increasing or decreasing trends for men aged older than 
or equal to 75 years [5,8,9]. These studies were smaller and did not include the 2014 cancer 
incidence data. Using the 2004—2014 USCS data, we found a significant increase in 
distant-stage prostate cancer incidence among men aged 50—64 and 75—84 years. A 
significant increase was also observed among white men, which confirms findings reported 
by Dalela et al. [9] Despite the differences in prostate cancer screening recommendations 
among major medical organizations [2,11,12], studies have shown that prostate cancer 
incidence and PSA-based screening rates declined after the United States Preventive 
Services Task Force issued the “D” recommendations for prostate cancer screening in 2012 
[3—5]. Because of the long natural history of prostate cancer and only two additional years’ 
cancer incidence data after 2012 available for analysis, long-term studies are needed to 
discern increased rates of distant cancer were a result of decreased screening. These studies 
will help to inform the development of future prostate cancer screening recommendations.
This study has at least five limitations. First, full case ascertainment may impede timely 
reporting of prostate cancer cases; however, delayed reporting likely caused underestimation 
of rates and increasing trends in the recent years. Second, trend analyses, a function of time, 
may be affected by outliers in a given year. Third, only two years of incidence data after 
2012 were available for analysis. Fourth, Joinpoint models choose the best fit segmented line 
with the smallest number of join points through several years of data. The pattern of the 
trend is sensitive to the number and location of join point and may partially contribute to 
differences in trends from previous studies. Last, we did not examine Gleason scores 
because they are not currently available in the USCS data set.
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Table 1
Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004—
2014
Characteristics Count Rate* 95% CI Years APC1† 95% CI Years APC2† 95% CI
Total 2,137,054 453.8 453.2—454.4 2004—2007 3.7 −3.7 to 11.7 2007—2014
−7.5‡ −9.3 to −5.6
Stage
    Localized 1,708,064 362.5 361.9—363.0 2004—2007 4.3 −3.8 to 13.1 2007—2014
−8.6‡ − 10.6 to −6.6
    Regional 233,245 46.3 46.1—46.5 2004—2007 2.9 −4.1 to 10.5 2007—2014
−3.2‡ −5.0 to ∑1.3
    Distant 84,954 19.5 19.4—19.7 2004—2010
− 1.2‡ −2.0 to −0.3 2010—2014 3.3‡ 1.6 to 5.0
    Unstaged 110,791 25.5 25.3—25.6 2004—2014
−4.4‡ −6.1 to −2.6
Localized
    Age
        50—54 years 126,885 109.9 109.3—110.5 2004—2009 3.4 −0.2 to 7.2 2009—2014
−8.9‡ −12.1 to −5.6
        55—59 years 240,578 235.4 234.5—236.3 2004—2008 3.5 −0.9 to 8.0 2008—2014
−8.1‡ −10.2 to −5.9
        60—64 years 327,540 394.7 393.4—396.1 2004—2007 6.3 − 1.9 to 15.2 2007—2014
−7.8‡ −9.7 to −5.8
        65—69 years 373,529 594.2 592.3—596.1 2004—2007 5.3 −3.9 to 15.3 2007—2014
−7.8‡ −10.0 to −5.5
        70—74 years 300,278 643.9 641.6—646.2 2004—2007 4.1 −4.3 to 13.3 2007—2014
−8.9‡ −11.0 to −6.9
        75—79 years 202,941 575.0 572.5—577.5 2004—2007 2.6 −5.7 to 11.6 2007—2014
−10.1‡ −12.1 to −8.1
        80—84 years 95,107 384.3 381.8—386.7 2004—2007 −0.6 −9.0 to 8.7 2007—2014
−11.6‡ −13.7 to −9.5
        85 + years 41,206 216.7 214.7—218.8 2004—2007 −2.8 − 10.6 to 5.6 2007—2014
−13.2‡ −15.2 to −11.3
    Race
        White 1,380,775 341.5 340.9—342.0 2004—2007 4.3 −4.0 to 13.4 2007—2014
−9.1‡ −11.1 to −7.1
        Black 244,065 544.0 541.8—546.3 2004—2008 1.5 −2.2 to 5.2 2008—2014
−7.8‡ −9.6 to −6.0
        API 6296 181.5 176.6—186.4 2004—2009 −2.2 −5.6 to 1.3 2009—2014
−11.7‡ −14.7 to −8.5
        AIAN 32,356 182.6 180.5—184.6 2004—2011
−5.1‡ −7.5 to —2.6 2011—2014 −15.0‡ −22.8 to −6.4
    Ethnicity
        Non-Hispanic 1,605,664 368.7 368.1—369.2 2004—2007 4.5 −3.8 to 13.5 2007—2014
−8.6‡ −10.6 to −6.5
        Hispanic 102,161 293.6 291.7—295.5 2004—2008 0.0 −3.2 to 3.3 2008—2014
−9.4‡ −10.9 to −7.8
Regional
    Age
        50—54 years 24,586 21.3 21.0—21.6 2004—2009 0.9 −2.9 to 4.8 2009—2014
−6.0‡ −9.5 to −2.3
        55—59 years 44,333 43.4 43.0—43.8 2004—2010 −0.6 −3.5 to 2.3 2010—2014
−5.7‡ −10.7 to −0.4
        60—64 years 57,258 69.0 68.4—69.6 2004—2007 3.3 −4.2 to 11.3 2007—2014
−4.1‡ −6.0 to −2.1
        65—69 years 56,593 90.0 89.3—90.8 2004—2010 1.0 − 1.6 to 3.7 2010—2014
−5.7‡ −10.3 to −1.0
        70—74 years 30,332 65.0 64.3—65.8 2004—2007 4.4 −2.2 to 11.5 2007—2014 −1.5 −3.2 to 0.2
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Characteristics Count Rate* 95% CI Years APC1† 95% CI Years APC2† 95% CI
        75—79 years 11,651 33.0 32.4—33.6 2004—2014 −0.8 − 1.8 to 0.3
        80—84 years 5146 20.8 20.2—21.4 2004—2014
−2.7‡ −4.3 to −1.1
        85 + years 3346 17.6 17.0—18.2 2004—2014
−3.7‡ −5.2 to −2.2
    Race
        White 196,138 45.7 45.5—45.9 2004—2007 3.0 −4.2 to 10.9 2007—2014
−3.3‡ −5.1 to −1.4
        Black 28,288 56.3 55.6—57.0 2004—2014
−1.6‡ −2.6 to −0.5
        API 947 23.2 21.6—24.8 2004—2014
−3.2‡ −5.9 to −0.4
        AIAN 5280 26.7 25.9—27.4 2004—2011 1.0 −2.0 to 4.1 2011—2014 −9.5 −19.1 to 1.2
    Ethnicity
        Non-Hispanic 218,892 47.2 47.0—47.5 2004—2007 3.1 −4.1 to 10.9 2007—2014
−3.1‡ −5.0 to −1.2
        Hispanic 14,336 36.5 35.8—37.1 2004—2014
−2.1‡ −3.0 to −1.2
Distant
    Age
        50—54 years 4480 3.9 3.8—4.0 2004—2014 2.0* 0.9 to 3.0
        55—59 years 8484 8.3 I 2004—2014 2.8* 1.5 to 4.1
        60—64 years 11,898 14.3 14.1—14.6 2004—2008 −2.1 −5.9 to 1.9 2008—2014 3.5‡ 1.3 to 5.7
        65—69 years 13,310 21.2 20.8—21.5 2004—2014 −0.4 − 1.5 to 0.7
        70—74 years 12,847 27.5 27.1—28.0 2004—2008 −2.1 −5.6 to 1.5 2008—2014 1.9 0.0 to 3.9
        75—79 years 12,405 35.1 34.5—35.8 2004—2011
−1.4* −2.4 to —0.4 2011—2014 5.1‡ 1.2 to 9.1
        80—84 years 11,372 45.9 45.1—46.8 2004—2010
−2.4* −4.4 to —0.2 2010—2014 4.2‡ 0.1 to 8.5
        85 + years 10,158 53.4 52.4—54.5 2004—2014 −0.5 − 1.7 to 0.8
    Race
        White 65,709 17.5 17.4—17.7 2004—2010 −0.8 − 1.8 to 0.1 2010—2014 3.9‡ 2.1 to 5.7
        Black 16,062 41.1 40.4—41.8 2004—2010
−3.3* −4.9 to −1.8 2010—2014 0.3 −2.6 to 3.4
        API 476 15.8 14.2—17.4 2004—2014 −0.4 −3.3 to 2.6
        AIAN 2005 12.6 12.0—13.2 2004—2014 −1.2 −3.2 to 0.8
    Ethnicity
        Non-Hispanic 78,399 19.4 19.3—19.6 2004—2010
−1.1* − 1.9 to −0.3 2010—2014 3.5‡ 1.9 to 5.1
        Hispanic 6553 20.9 20.4—21.5 2004—2011
−2.9* −3.9 to −1.9 2011—2014 2.9 −1.0 to 7.0
Unstaged
    Age
        50—54 years 4555 3.9 3.8—4.1 2004—2014 0.7 − 1.5 to 3.0
        55–59 years 9477 9.3 9.1 —9.5 2004—2014 1.0 −0.8 to 2.9
        60–64 years 15,082 18.2 17.9—18.5 2004—2009 3.3 − 1.5 to 8.2 2009—2014 −3.9 −8.3 to 0.8
        65–69 years 19,879 31.6 31.2—32.1 2004—2014 −1.1 −3.4 to 1.1
        70–74 years 20,362 43.7 43.1—44.3 2004—2010 0.4 −4.6 to 5.6 2010—2014
−9.4‡ −17.6 to −0.5
        75–79 years 18,539 52.5 51.8—53.3 2004—2007 1.9 −9.5 to 14.8 2007—2014
−7.9‡ −10.8 to −4.9
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Characteristics Count Rate* 95% CI Years APC1† 95% CI Years APC2† 95% CI
        80—84 years 13,162 53.2 52.3—54.1 2004—2007 −2.0 − 11.8 to 9.0 2007—2014
−10.9‡ −13.4 to −8.3
        85 + years 9735 51.2 50.2—52.2 2004—2007 −3.6 −13.1 to 7.0 2007—2014
−12.9‡ −15.3 to −10.4
    Race
        White 76,699 20.5 20.3—20.6 2004—2014
−7.0* −8.9 to −5.2
        Black 14,995 39.2 38.5—39.9 2004—2014
−5.0* −6.6 to −3.3
        API 587 20.9 19.1—22.9 2004—2014
−4.6* −7.4 to −1.6
        AIAN 2341 15.0 14.4—15.7 2004—2010 6.3 −0.2 to 13.4 2010—2014 −9.3 −19.5 to 2.2
    Ethnicity
        Non-Hispanic 100,599 24.9 24.7– 25.0 2004–2014
−4.4‡ −6.1 to −2.7
        Hispanic 9975 33.5 32.8– 34.2 2004–2009 5.0 −3.7 to 14.5 2009–2014
− 12.3‡ −19.6 to −4.3
APC = Annual Percentage Change; API = Asian or Pacific Islander; AIAN = American Indian/Alaska Native; Cl = confidence interval.
*
Rates are per 100,000 and rates for all variables except age are age-adjusted to the 2000 U.S. Standard Population (19 age groups—Census P25–
1130).
†
Trends were measured with annual percentage change in rates and were considered to increase or decrease if P < .05; otherwise trends were 
considered stable.
‡P < .05.
CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program.
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